The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00539786

Enrollment

100

Registered

2007-10-05

Start date

2006-03-31

Completion date

Unknown

Last updated

2014-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease

Keywords

Patients with extraesophageal manifestation of gastroesophageal reflux disease

Brief summary

PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.

Interventions

DRUGProton pump inhibitor (rabeprazole)

Patients receives rabeprazole 20mg AM and 20mg PM for 14 days

Study design

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with extraesophageal manifestation symptoms of GERD

Exclusion criteria

* laryngeal, pharyngeal, liver, lung, renal, or hematological disorders * a history of gastrointestinal surgery, and a history of connective tissue disorders. * patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy

Design outcomes

Primary

Measure	Time frame
Symptom responders after PPI trials	2 weeks after PPI trials

Countries

South Korea

Contacts

Primary ContactTae ggon Kim

tggo.kim@samsung.com+82-2-3410-2975

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026